Why the study?
Does fasudil improve pulmonary and left ventricular haemodynamics in patients with pulmonary hypertension associated with HFpEF?
Does fasudil improve pulmonary and left ventricular haemodynamics in patients with pulmonary hypertension associated with HFpEF?
Fasudil may be a promising targeted therapy for improving hemodynamics in patients with pulmonary hypertension associated with HFpEF.
Hypothesis-generating for fasudil in PH-HFpEF; leaves open need for randomized outcome trials.
The Rho kinase inhibitor fasudil can improve pulmonary and left ventricular haemodynamics in patients with PH-HFpEF. The total effective rate was higher in the RPH group. Fasudil may be a promising targeted drug for the RPH in PH-HFpEF patients. This trial is registered with ChiCTR-INR-16009511.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: